Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology MFM
- Rapid whole exome sequencing in pregnancies to identify the underlying genetic cause in fetuses with congenital anomalies detected by ultrasound imaging.Prenat Diagn. 2020; 40: 972-983
- Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities.Prenat Diagn. 2015; 35: 1010-1017
- Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study.Lancet. 2019; 393: 747-757
- Fetal hydrops and the Incremental yield of Next-generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis.Ultrasound Obstet Gynecol. 2021; 58: 509-518
- Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study.Lancet. 2019; 393: 758-767
- Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis.N Engl J Med. 2020; 383: 1746-1756
- Next-generation sequencing to diagnose suspected genetic disorders.N Engl J Med. 2019; 380: 201
- Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.PLoS One. 2017; 12e0170843
- Next-generation diagnostics: gene panel, exome, or whole genome?.Hum Mutat. 2015; 36: 648-655
- Non-immune hydrops fetalis: a short review of etiology and pathophysiology.Am J Med Genet A. 2012; 158A: 597-605
- A system-based approach to the genetic etiologies of non-immune hydrops fetalis.Prenat Diagn. 2019; 39: 732-750
- Non-immune hydrops fetalis: a prospective study of 53 cases.Am J Med Genet A. 2013; 161A: 3078-3086
- Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #7: nonimmune hydrops fetalis.Am J Obstet Gynecol. 2015; 212: 127-139
- Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents?.Prenat Diagn. 2011; 31: 186-195
- Nonimmune hydrops fetalis: identifying the underlying genetic etiology.Genet Med. 2019; 21: 1339-1344
- Epidemiology of live born infants with nonimmune hydrops fetalis-insights from a population-based dataset.J Pediatr. 2017; 187 (e3): 182-188
- Etiology and outcome of hydrops fetalis: report of 62 cases.Pediatr Neonatol. 2014; 55: 108-113
- Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis.Prenat Diagn. 2020; 40: 492-496
- Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era.J Med Genet. 2019; 56: 654-661
GeneDx. 2020. Available at: https://www.genedx.com/. Accessed 06/01/2020.
CGC Genetics. 2020. Available at: https://www.cgcgenetics.com/en. Accessed 06/01/2020.
Integrated Genetics. 2020. Available at: https://integratedgenetics.com/. Accessed 06/01/2020.
Prevention Genetics. 2020. Available at: https://www.preventiongenetics.com/. Accessed 06/01/2020.
Invitae. 2020. Available at: https://www.invitae.com/en/. Accessed 06/01/2020.
ARUP Laboratories. XXX. 2020.Available at: https://www.aruplab.com/genetics. Accessed 06/01/2020.
- Exome sequencing vs targeted gene panels for the evaluation of nonimmune hydrops fetalis.Am J Obstet Gynecol. 2022; 226 (128.e1–11)
- Nonimmune hydrops fetalis: genetic analysis and clinical outcome.Prenat Diagn. 2020; 40: 803-812
- The many faces of hydrops.J Pediatr Surg. 2015; 50: 50-54
- Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis.Early Hum Dev. 2011; 87: 571-575
- Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis.J Obstet Gynaecol Res. 2016; 42: 385-391
- Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment.Acta Obstet Gynecol Scand. 2001; 80: 726-730
- Etiology and outcome of second trimester non-immunologic fetal hydrops.Acta Obstet Gynecol Scand. 2000; 79: 15-18
- Risk of critical congenital heart defects by nuchal translucency norms.Am J Obstet Gynecol. 2015; 212 (518.e1–10)
- Karyotype and outcome of fetuses diagnosed with cystic hygroma in the first trimester in relation to nuchal translucency thickness.Prenat Diagn. 2006; 26: 369-372
- Births: final data for 2017.Natl Vital Stat Rep. 2018; 67: 1-50
- Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.Eur J Hum Genet. 2013; 21: 936-942
- Evaluation and classification of severity for 176 genes on an expanded carrier screening panel.Prenat Diagn. 2020; 40: 1246-1257
- Systematic classification of disease severity for evaluation of expanded carrier screening panels.PLoS One. 2014; 9e114391
Labcorp. 2020. Available at: https://www.labcorp.com/. Accessed 06/01/2020.
Greenwood Genetic Center. 2020. Available at: https://www.ggc.org/. Accessed 06/01/2020.
- Costs and consequences of comprehensive stillbirth assessment.Am J Obstet Gynecol. 2002; 186: 1027-1034
- The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis.J Clin Virol. 2019; 114: 12-20
- Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring.Int J Epidemiol. 2013; 42: 1070-1076
The Regents of the University of California. 2020. Available at: https://humangenetics.ucsf.edu/. Accessed 06/01/2020.
- Out-of-pocket costs and insurance coverage for abortion in the United States.Womens Health Issues. 2014; 24: e211-e218
- Hospital costs associated with stillbirth delivery.Matern Child Health J. 2013; 17: 1835-1841
- Birth hospitalization costs and days of care for mothers and neonates in California, 2009-2011.J Pediatr. 2019; 204 (e14): 118-125
- A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States.PLoS One. 2015; 10e0131402
- Pediatric healthcare costs for patients with 22q11.2 deletion syndrome.Mol Genet Genomic Med. 2017; 5: 631-638
Centers for Medicare and Medicaid Services. cms.gov. 2017. Available from: www.cms.gov. Accessed 06/01/2020.
- A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy.Epilepsia. 2018; 59: 1177-1187
- Preference assessment of prenatal diagnosis for Down syndrome: is 35 years a rational cutoff?.Prenat Diagn. 2002; 22: 1195-1200
- Prenatal testing in the genomic age: clinical outcomes, quality of life, and costs.Obstet Gynecol. 2015; 126: 737-746
- Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents.JAMA. 1999; 281: 1991-1997
- Cost utility of prenatal diagnosis and the risk-based threshold.Lancet. 2004; 363: 276-282
- Vestronidase Alfa: a review in mucopolysaccharidosis VII.BioDrugs. 2019; 33: 233-240
M.E.N. is a consultant to Invitae and Luna Genetics and has received research funding from Natera, but this funding was not applied to this study. The Center for Maternal-Fetal Medicine at the University of California, San Francisco, received gift funds from Ultragenyx for studies conducted through the Center, some of which were used to fund previous studies on hydrops. The other authors report no conflict of interest.
The funds from the National Institutes of Health (NIH; grant numbers 5K12HD001262-18 and U01HG009599) supported T.N.S. and M.E.N., respectively. The contents of the publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. T.N.S. is also supported by grants from the Doris Duke Charitable Foundation and the Brianna Marie Foundation in collaboration with the Fetal Health Foundation. The funding sources had no role in the study design; collection, analysis, or interpretation of data; writing of the report; or decision to submit the article for publication.
A poster on this topic was presented at the 42nd annual pregnancy meeting of the Society for Maternal-Fetal Medicine in virtual format January 31, 2022, to February 5, 2022.
Cite this article as: Avram CM, Caughey AB, Norton ME, et al. Cost-effectiveness of exome sequencing vs targeted gene panels for prenatal diagnosis of fetal effusions and nonimmune hydrops fetalis. Am J Obstet Gynecol MFM 2022;XX:x.ex–x.ex.